We undertake preclinical immunological work, Phase I, II and III trials and post-licensing evaluations. Our vision is to contribute to the clinical development and evaluation of vaccines that improve global health. Our strategy is to bring together our expertise in molecular and cellular immunology, community engagement, clinical trials and detailed demographic surveillance of a large population to position ourselves to become the centre of choice for institutions and funders seeking to trial new vaccines in Sub-Saharan Africa.